Skip to content

Home
Combination Testing
Resources
Patients
Contact Us

Menu

Home
Combination Testing
Resources
Patients
Contact Us

Physician Login

The utility of combined mutations and microRNA expression profiling in assessing cancer risk in thyroid nodules

To correlate real-world results of
- Bethesda (BDC) classification
- Mutation panel (ThyGENX™)
- Two-tiered (positive, negative) miRNA classifier (ThyraMIR™)
To examine the projected real-world absolute risk of cancer of BDC III and BDC IV nodules given mutation panel and miRNA classifier results1

Back to Combination Testing

Other Recent Evidence

Molecular Analysis Of Thyroid Malignancy Using Fna Cytology Smears By The Combined ThyGenX NGS And ThyraMIR™ miRNA Classifier Test: A Prospective Study

January 28, 2020

Correlation Between Mutations in Malignant Thyroid Nodules and Aggressive Tumor Behavior

January 28, 2020

Performance Attributes of Microdissected Slide-Format and Dedicated Needle Aspiration Biopsy Analysis of Indeterminate Thyroid Nodules

January 28, 2020

Diagnostic Molecular Profiling Differentiating Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP) from Closely Related Entities

January 28, 2020

Estimation Of Malignancy Association For Mutations And Fusions, Detected By NGS, By Incorporating The Results Of microRNA Expression Profiling Assay For A Large Set Of Clinical Specimens

January 28, 2020

The Majority of Non-‐Diagnostic (Insufficient) Thyroid Nodule Cytology Samples Can Effectively Undergo Molecular (Combined Muta4onal and MicroRNA Classifier) Analysis Using a Needle Aspiration Approach

January 28, 2020

Facebook-f Twitter Linkedin-in

Terms of Use
Privacy Policy
HIPAA Privacy

Menu

Terms of Use
Privacy Policy
HIPAA Privacy

Interpace Diagnostics is a registered trademark and business unit of Interpace Biosciences, Inc.™
©2019 Interpace Biosciences, Inc.™ All rights reserved.

844-405-9655
info@interpacedx.com

Scroll to Top